IBJNews

Eli Lilly's profit shoots up despite lackluster sales

Back to TopCommentsE-mailPrintBookmark and Share

Shares of Eli Lilly and Co. fell about 3 percent in morning trading Wednesday after the drugmaker reported better-than-expected earnings, but flat revenue, for the first quarter.

Lilly also said regulators had agreed to a priority review of the company's potential stomach cancer treatment.

The Indianapolis-based company said the Food and Drug Administration will evaluate ramucirumab under a program designed for drugs that treat serious or life-threatening diseases for which there are few other therapies. Fast-track, or priority, status gives companies extra meetings and correspondence with regulators throughout the review process, and it allows the drugmaker to submit data as it compiles it.

Lilly is seeking approval for ramucirumab as a second treatment in patients with gastric and gastroesophageal junction cancers that have spread. Gastric cancer affects the stomach lining and often goes undetected while developing slowly. Gastroesophageal junction cancer forms where the esophagus connects to the stomach.

The company said last year that the experimental drug met goals for improved patient survival in late-stage clinical research.

Lilly also recently submitted a new type 2 diabetes treatment it developed with German drugmaker Boehringer Ingelheim to the FDA. The company said Wednesday that treatment and ramucirumab are the first two of what could be five drugs submitted to U.S. regulators this year.

Investors are watching Lilly's pipeline of developing drugs closely because the company is losing U.S. patent protection for some key products, and it needs to replace that revenue. Lilly lost patent protection for its all-time best selling drug, the antipsychotic Zyprexa, in late 2011, and its sales have plunged since being exposed to cheaper generic competition. The company also loses protection at the end of this year for current top-seller, the antidepressant Cymbalta.

In the first quarter, Lilly's earnings jumped 53 percent largely due to a $495 million payment for the transfer to former drug development partner Amylin Pharmaceuticals of commercial rights outside the United States for the diabetes treatment exenatide.

Lilly earned $1.55 billion, or $1.42 per share, in the three months that ended March 31. That compares to $1.01 billion, or 91 cents per share, in last year's quarter.

Not counting the exenatide payment, Lilly reported adjusted earnings of $1.14 per share. Analysts expected, on average, earnings of $1.05 per share, according to FactSet.

The drugmaker said its revenue stayed flat at $5.6 billion, as lower sales volume and unfavorable foreign exchange rates countered gains from higher prices. Analysts expected $5.67 billion in revenue.

Revenue from Cymbalta rose 19 percent, to $1.33 billion, and sales of the erectile dysfunction drug Cialis climbed 11 percent, to $515 million. But revenue from Zyprexa tumbled 49 percent, to $284.8 million.

The drugmaker also reaffirmed its forecast for 2013 earnings to range between $3.82 and $3.97 per share on $22.6 billion to $23.4 billion in revenue.

Analysts expect, on average, earnings of $3.90 per share on $23 billion in revenue.

Lilly shares were down 2.8 percent near midday, to $56.75 each. The company's stock price had risen 18.3 percent this yea after closing Tuesday at $58.33. It has been lifted by the broader markets and by investors’ rising hopes in the pipeline potential of all pharmaceutical companies.

 

ADVERTISEMENT

Post a comment to this story

COMMENTS POLICY
We reserve the right to remove any post that we feel is obscene, profane, vulgar, racist, sexually explicit, abusive, or hateful.
 
You are legally responsible for what you post and your anonymity is not guaranteed.
 
Posts that insult, defame, threaten, harass or abuse other readers or people mentioned in IBJ editorial content are also subject to removal. Please respect the privacy of individuals and refrain from posting personal information.
 
No solicitations, spamming or advertisements are allowed. Readers may post links to other informational websites that are relevant to the topic at hand, but please do not link to objectionable material.
 
We may remove messages that are unrelated to the topic, encourage illegal activity, use all capital letters or are unreadable.
 

Messages that are flagged by readers as objectionable will be reviewed and may or may not be removed. Please do not flag a post simply because you disagree with it.

Sponsored by
ADVERTISEMENT

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
 
Subscribe to IBJ
  1. Good Day I am Mr (Victoria Wright) from United state of America, i stayed in NEW YORK, and i have a broke up business, until i found this company email who help me to gain a loan for business,, and now i want to used this short medium to congratulate the below company for the fast and safe money they loan to me without any form of collateral, i loan 500,000USD from the company to save my business and lots more, i saw their mail on the internet, everyone always give testimony for what they did, so i quickly contacted them and they all did everything for me without stress and my money was sent to my account just 3 days later, i was surprise and i feel so glad, now i have a standard business control agent who help me, now i will advice those who need urgent loan to contact him at the bellow email:zenithfirm12@gmail.com

  2. NOTICE:This is to inform the general public that Vampires are real. My name is James Franklyn.,am an agent of vampire,am here to introduce our new world trend to you,a world of vampire where life get easier,we have made so many persons vampires and have turned them rich,you will be assured long life and prosperity,you shall be made to be very sensitive to mental alertness,stronger and also very fast,you will not be restricted to walking at night only even at the very middle of broad day light you will be made to walk.In case you are wildly oppressed by some unscrupulous persons we can still help you fight them.Your protection is assured immediately you join.Just contact the bellow email if you are interested we are here to attend to you anytime you want us. Contact the bellow email for more details. Email:vampirescreed@hotmail.com Sincerely: James Franklyn.

  3. Bravo! Someone else that is willing to speak the truth! Bravo!_____NBCSN is available in almost 2 MILLION more homes than just a few years ago, but Indycar STILL gets less total viewers than it did just a few years ago when NBC took over Versus. Attendance and ratings cratered with the end of season races (just when the title battle got "interesting" HAH!__________And now...new race in Basilia, where Miles celebrated the "rich history" of Indycar racing there. Rich history? What, 7 events in the 100 years of AOW? Yep, some history. Well, at least its an oval. It's not??? Are you kidding me??? Gosh darn road racin furriners.

  4. PURITY RAY LOAN OFFER........ Have you been denied by your banks,or are you in need of of an urgent loan to pay of your bills we are capable of giving loans @ cheaper rate to interested individuals, student, companies and members of the public in need of finance to settle bills, we do offer considerable loans which you can count on. For more information on our various types of loan,then you will have to contact PURITY RAY LOAN FIRM, to help you achieve your desire LOAN APPLICATION FORM TO BE FILLED BORROWERS INFORMATION * Full name:………………………. * SEX * ……………………………. * Country………………………….. * State:……………………………. * Land:…………………………….. * Occupation:…………………….. * phone number:…………………. * Telephone: ………………………….. * Age:………………………………. * Amount needed as loan:……… * Loan Duration:………………….. * Propose of Loan:……………….. * Annual revenue:………………… * Monthly Income:……………….. * Guarantee:………………………. * Payment: monthly or annually Email.....purityrayloanfirm@gmail.com Thank you and God bless Mr Purity Ray PURITY RAY LOAN FIRM we tend to serve you better

  5. Problem: most of the people responding to this article don't know about this service AT ALL! Why? Lack of awareness. This isn't IndyGo. This is CIRTA: might as well be the mattress company because they are asleep at the wheel - something like 3 directors over the last year? Playing with federal grant money is great! This "region" wants commuter rail service, has spent MILLIONS on Transportation studies yet can't even support a commuter bus line? This is largely for suburban riders to get to downtown - not for "service people to work in our hotels and restaurants" ! Get your head out of your backside!! These are professionals, students etc. that don't want to fight traffic, save some money on parking, gas, stress.... if CIRTA would put their federal money into widely promoting the sevive to Greenwood, Fishers & Carmel instead of finding directors and studies - this would be a successful service. Our family uses(d) it daily for the last several years - but the recent uncertainty & now unreliability due to cuts from Carmel has been a problem. Now, costs us an additional $350/month for gas & parking ( $4200/year) plus vehicle wear, service, environmental impact ... YES - this REGION needs this this type of service in order to keep growing and getting the people it needs to fill skilled positions in downtown Indianapolis. Think outside of your own car !!!

ADVERTISEMENT